On the other hand, lung cancer guidelines recommend EGFT-TKIs as first-line therapy for advanced or recurrent NSCLC with an uncommon EGFR mutation other than the exon 20 insertion mutation [7]. Here, EGFR is linked to non-small cell lung carcinoma.